Latest & greatest articles for parkinson's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on parkinson's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for parkinson's disease

1. Levodopa (Inbrija) - Parkinson’s disease

Levodopa (Inbrija) - Parkinson’s disease Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/452546/2019 EMEA/H/C/004786 Inbrija (levodopa) An overview of Inbrija and why (...) it is authorised in the EU What is Inbrija and what is it used for? Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement). Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase. Inbrija contains the active substance

2019 European Medicines Agency - EPARs

2. Canadian guideline for Parkinson disease

Canadian guideline for Parkinson disease APPENDIX 1: CANADIAN GUIDELINE FOR PARKINSON DISEASE, 2 ND EDITION www.parkinson.ca www.ParkinsonClinicalGuidelines.ca Parkinson-final-E.indd 1 2019-09-05 2:39 PMNote: This full version of the Canadian Guideline for Parkinson Disease has been copyedited to be consistent with the summary article published in CMAJ, but has not been peer reviewed. English printed: 978-1-897490-48-8 English electronic: 978-1-897490-49-5 Parkinson-final-E.indd 2 2019-09-05 2 (...) :39 PMTABLE OF CONTENTS Parkinson-final-E.indd 3 2019-09-05 2:39 PMINTRODUCTION ________________ 6 COMMUNICATION ____________ 12 DIAGNOSIS AND PROGRESSION _______________ 15 TREATMENT _________________ 19 NONMOTOR FEATURES OF PARKINSON DISEASE _______ 28 PALLIATIVE CARE _____________ 36 SUPPLEMENTAL MATERIAL _____ 38 REFERENCES _________________ 51 COMMUNICATION n People with Parkinson disease should be encouraged to participate in choices about their own care. n Communication should be in verbal

2019 CPG Infobase

3. Safinamide (Onstryv) - idiopathic Parkinson's disease

Safinamide (Onstryv) - idiopathic Parkinson's disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

4. Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial

Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson disease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined (...) effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of Parkinson Disease, Movement Disorders and Brain Injury Rehabilitation

2019 EvidenceUpdates

5. Randomized trial of care management to improve Parkinson disease care quality

Randomized trial of care management to improve Parkinson disease care quality To test effects on care quality of Chronic Care Model-based Parkinson disease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only

2019 EvidenceUpdates

6. Aquatic exercise improves motor impairments in people with Parkinson`s disease, with similar or greater benefits than land-based exercise: a systematic review

Aquatic exercise improves motor impairments in people with Parkinson`s disease, with similar or greater benefits than land-based exercise: a systematic review What are the effects of aquatic exercise on disease severity, (non-)motor impairments, activity performance, fear of falling, and quality of life in people with Parkinson's disease (PD)? Does aquatic exercise have greater effects on these outcomes than other forms of exercise in people with PD?Systematic review and meta-analysis (...) in the Unified Parkinson's Disease Rating Scale Part III (MD -4.6, 95% CI -7.5 to -1.7) in favour of aquatic exercise. Six studies compared aquatic exercise with land-based exercise after intervention (mean 7.2 weeks of training (SD 2.2); 159 participants). The effect of aquatic exercise was superior to land-based exercise on the Berg Balance Scale (MD 2.7, 95% CI 1.6 to 3.9), the Falls Efficacy Scale (MD -4.0, 95% CI -6.1 to -1.8) and the 39-item Parkinson's Disease Questionnaire (MD -6.0, 95% CI -11.3

2019 EvidenceUpdates

7. Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study

Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinson disease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, Parkinson Disease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate

2019 EvidenceUpdates

8. Bright light therapy for depression in Parkinson disease: A randomized controlled trial

Bright light therapy for depression in Parkinson disease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinson disease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic

2019 EvidenceUpdates

9. Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. (PubMed)

Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. Deficits in step-to-step symmetry and trunk muscle activations have been linked to falls in Parkinson disease. Given such symptoms are poorly managed with anti-parkinsonian medications, alternate therapies are needed. This blind phase II randomized controlled trial sought to establish whether exercise can improve step-to-step symmetry in Parkinson disease.Twenty-four Parkinson disease (...) , active interventions seem more suited to increasing independence and quality of life for people with Parkinson disease.Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to do the following: (1) Describe the effect deficits in trunk muscle function have on gait in individuals with Parkinson disease; (2) Identify the benefits of targeted trunk exercises on step-to-step symmetry

2019 American journal of physical medicine & rehabilitation

10. Path Finder for freezing of gait in people with Parkinson?s disease

Path Finder for freezing of gait in people with Parkinson?s disease P Path Finder for freezing of gait in people with ath Finder for freezing of gait in people with P Parkinson arkinson’s disease ’s disease Medtech innovation briefing Published: 25 January 2019 nice.org.uk/guidance/mib170 pathways Summary Summary The technology technology described in this briefing is Path Finder laser shoe attachment. It is used as a walking aid and is designed to help prevent freezing of gait in people (...) with Parkinson's disease. The inno innovativ vative aspects e aspects are that it is currently the only hands-free visual-cueing device for people with Parkinson's disease available in the UK. The intended place in ther place in therap apy y would be in place of other visual-cue walking aids but together with a reduced number of physiotherapy sessions, depending on the individuals' disease stage and personal preference. It would be used by the patient in their home or in the physiotherapy clinic. It may also

2019 National Institute for Health and Clinical Excellence - Advice

11. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson`s disease: a randomised, double-blind, placebo-controlled phase 3 trial

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson`s disease: a randomised, double-blind, placebo-controlled phase 3 trial Patients with Parkinson's disease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients (...) with Parkinson's disease during off periods.In this randomised, double-blind, placebo-controlled, phase 3 trial, patients were recruited at 65 sites in Canada, Poland, Spain, and the USA. Eligible participants were patients with Parkinson's disease aged 30-85 years, who had daily off periods of 2 h or longer and showed an improvement of 25% or greater in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score from off to on state after use of an oral levodopa plus a dopa-decarboxylase inhibitor

2019 EvidenceUpdates

12. ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease

‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Discover Portal Discover Portal ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Published on 23 March 2016 doi: Physiotherapy and occupational therapy do not help people with mild (...) to moderate Parkinson’s disease to lead more independent lives. This NIHR-funded randomised controlled trial of adults with Parkinson’s disease did not find any difference between the therapy group and a no-therapy control group at up to 15 months in any of the four measures of activities of daily living: mobility, kitchen activities, domestic tasks or leisure activities. The average ‘dose’ of the therapies was four sessions of 58 minutes over eight weeks for both therapies combined. The number

2019 NIHR Dissemination Centre

13. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. (PubMed)

Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated.In a multicenter, double-blind, placebo-controlled, delayed-start trial, we randomly assigned patients with early Parkinson's disease to receive levodopa (100 mg three times per day (...) ) in combination with carbidopa (25 mg three times per day) for 80 weeks (early-start group) or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks (delayed-start group). The primary outcome was the between-group difference in the mean change from baseline to week 80 in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe disease). Secondary analyses included the progression of symptoms

2019 NEJM

14. A randomized controlled study of whether setting specific goals improves the effectiveness of therapy in people with Parkinson`s disease

A randomized controlled study of whether setting specific goals improves the effectiveness of therapy in people with Parkinson`s disease To evaluate the effects of an intervention based on a specific set of goals on goal attainment, manual dexterity, hand grip strength and finger prehension force compared to a standardized approach in patients with Parkinson's disease.Randomized controlled trial.Home-based.Fifty patients with a clinical diagnosis of Parkinson's disease acknowledging impaired (...) arm 10.55 ± 1.95 vs. 7.33 ± 3.63 pins, P < 0.001) and finger prehension force (postintervention values in the most affected arm 8.03 ± 1.93 vs. 6.31 ± 1.85 kg, P = 0.010).Targeting therapy toward specific goals leads to greater changes in arm function than a standardized approach in people with Parkinson's disease.

2019 EvidenceUpdates

15. Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial. (PubMed)

Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial. Background: Non-motor symptoms such as sleep disturbance, cognitive decline, fatigue, anxiety, and depression in Parkinson's disease (PD) impact quality of life. Increased levels of pro-inflammatory cytokines in individuals with PD have been reported, which may contribute to non-motor symptoms. A mind-body exercise, Qigong, has demonstrated benefits

Full Text available with Trip Pro

2019 Medicines (Basel, Switzerland)

16. Acupuncture for treatment of tremor symptom in Parkinson's disease: a protocol for the systematic review and meta-analysis of randomized controlled trials

Acupuncture for treatment of tremor symptom in Parkinson's disease: a protocol for the systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models

2019 PROSPERO

17. The effect of exercise on pain in people with Parkinson's disease: a systematic review

The effect of exercise on pain in people with Parkinson's disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how

2019 PROSPERO

18. Self-management interventions in Parkinson's Disease: a systematic review and meta-analysis

Self-management interventions in Parkinson's Disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

19. Proton MR spectroscopy for the early diagnosis of Parkinson's disease in the substantia nigra and globus pallidus: a meta-analysis

Proton MR spectroscopy for the early diagnosis of Parkinson's disease in the substantia nigra and globus pallidus: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units

2019 PROSPERO

20. The effectiveness of rhythmic auditory stimulation on postural balance and gait parameters for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

The effectiveness of rhythmic auditory stimulation on postural balance and gait parameters for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility (...) species); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease

2019 PROSPERO